But one of the lingering questions about the vaccine deployment can vaccine developers pump out enough vials to keep up with demand fires CEO Albert Bourla told Reuters in a TV interview Thursday that his company is doing its part and is likely to exceed its vaccine production targets by as much as 20% this year.

We announced that we felt that we will be able to do $2 billion is by the end of this year.

I reviewed a couple of days ago our situation and the readiness and we're going to do way more.

We will exceed clearly this year.

The $2 billion is and our steady state, which will say full on an annual basis.

In two years we will be able to make a $3 billion boilers production.

Optimism comes amid new real World data from Pfizer and Partner Beyond Tech, which suggests its vaccine is largely effective and preventing virus spread by those without symptoms.

The most impressive is that is the first time that we got data about a symptomatic infections, and the data reveals of far 94% effectiveness against the symptomatic infections.

This is very, very important for society, not for the individuals, because they don't have any symptoms.

But they are the ones but clearly, uh, replicate the virus into society because they don't know that they have it.

And they don't take the measures of isolation that those that they have it take.

And they, of course, they spread the virus.

The data show Pfizer's current vaccine is effective on the original Covid 19 strain and on the emerging and highly contagious UK variant.

More tests need to be done on a variant discovered in South Africa.

Pfizer is ready to tweak the vaccine if need be.